KEYLYNK-010

Trial description
A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next generation Hormonal Agent (NHA) and Chemotherapy 
Contact name
Dr Danish Mazhar
Trial start date
Tuesday, September 24, 2019
Trial end date
Tuesday, June 30, 2020
Trial tumour type
Prostate
Show on Radiotherapy
No